Abstract
Researchers at the Mater Medical Research Institute, The University of Queensland and GlycoMimetics have mouse data showing that E selectin antagonists can alleviate side effects of chemotherapy brought about by exhaustion of the self-renewal capacity of hematopoietic stem cells. The group is working together to develop E selectin antagonists, but Mater Research and the biotech have different agendas about how to use those antagonists in oncology.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
